Table 2.

Effect of intranasal vaccine immunogen challenges on biomarkers of naïve and RTA1-33/44-198-immunized BALB/c mice.

Endpoint a	Time point b	PBS challenge c	RTA1-33/44-198 challenge in immune naïve mice d		RTA1-33/44-198 challenge in immune mice e		Significance of naïve/immune difference (p)
		Mean ± S.D.	Mean ± S.D.	Significance of difference from PBS challenge (p)	Mean ± S.D.	Significance of difference from PBS challenge (p)
BALF protein (μg/mL)	Day 2	154 ± 10	178 ± 37	0.212	274 ± 66	<0.001	<0.001
	Day 13	139 ± 19	106 ± 14	<0.001	193 ± 39	0.005	<0.001
Blood glucose (mg%)	Day 2	184 ± 20	190 ± 20	0.573	228 ± 13	<0.001	<0.001
	Day 13	178 ± 14	194 ± 14	0.026	218 ± 25	<0.001	0.023
% initial weight	Day 1	96.7 ± 2.1	97.2 ± 1.8	0.399	94.6 ± 3.0	0.016	0.002
	Day 2	98.4 ± 2.2	100.1 ± 2.6	0.038	98.7 ± 3.0	0.746	0.137
	Day 13	99.6 ± 3.0	105.1 ± 3.0	<0.001	102.9 ± 2.6	0.017	0.088

^a BALF: bronchoalveolar lavage fluid; ^b Days after the intranasal RTA1-33/44-198 vaccine challenge; ^c Mice were vaccinated with 10 μg doses of RTA1-33/44-198 with Rehydrogel adjuvant as described in Materials and Methods. Intranasal challenge was with PBS. S.D.: one standard deviation; ^d Mice received sham vaccine (adjuvant only) with the same schedule as described for the PBS challenge group. Intranasal challenge was with RTA1-33/44/198 in an amount equimolar with 10 LD50 ricin. S.D.: one standard deviation; ^e Mice were vaccinated with 10 μg doses of RTA1-33/44-198 with Rehydrogel adjuvant as described in Materials and Methods. Intranasal challenge was with RTA1-33/44/198 vaccine immunogen in an amount equimolar with 10 LD50 ricin. S.D.: one standard deviation.